Tirzepatide Once Weekly for the Treatment of Obesity

What Was Tested

The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

Obesity is a chronic disease that results in substantial global morbidity and mortality.

Who Took Part

According to the abstract, 2539 adults were involved.

PubMed indexes the participants as adults.

The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the adults and researchers unaware of who received Tirzepatide.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Anti-Obesity Agents, Gastric Inhibitory Polypeptide, Glucagon-Like Peptides, Obesity, Weight Loss and Tirzepatide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in 2539 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The New England journal of medicine), a journal based in United States.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page.